Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) and Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.
Earnings & Valuation
This table compares Cellectar Biosciences and Guided Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cellectar Biosciences | N/A | N/A | -$21.79 million | ($6.66) | -0.33 |
| Guided Therapeutics | $770,000.00 | 25.42 | -$3.20 million | ($0.04) | -5.07 |
Analyst Ratings
This is a summary of current ratings and recommmendations for Cellectar Biosciences and Guided Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cellectar Biosciences | 1 | 0 | 3 | 0 | 2.50 |
| Guided Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Cellectar Biosciences presently has a consensus price target of $11.00, indicating a potential upside of 393.27%. Given Cellectar Biosciences’ stronger consensus rating and higher possible upside, analysts clearly believe Cellectar Biosciences is more favorable than Guided Therapeutics.
Risk and Volatility
Cellectar Biosciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Guided Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500.
Insider and Institutional Ownership
16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 9.7% of Guided Therapeutics shares are held by institutional investors. 2.6% of Cellectar Biosciences shares are held by insiders. Comparatively, 66.8% of Guided Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Cellectar Biosciences and Guided Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cellectar Biosciences | N/A | -349.24% | -153.18% |
| Guided Therapeutics | N/A | N/A | -274.24% |
Summary
Guided Therapeutics beats Cellectar Biosciences on 6 of the 11 factors compared between the two stocks.
About Cellectar Biosciences
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
About Guided Therapeutics
Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
